These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 20428822

  • 21. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
    Pinson H, Hallaert G, Van der Meulen J, Dedeurwaerdere F, Vanhauwaert D, Van den Broecke C, Van Dorpe J, Van Roost D, Kalala JP, Boterberg T.
    J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
    Jung TY, Jung S, Moon KS, Kim IY, Kang SS, Kim YH, Park CS, Lee KH.
    Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840
    [Abstract] [Full Text] [Related]

  • 24. Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma.
    Lee A, Malakhov N, Sheth N, Wang A, Han P, Schreiber D.
    Clin Neurol Neurosurg; 2018 Jul; 170():127-131. PubMed ID: 29777945
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
    Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Löffler M, Weller M, Reifenberger G, Tonn JC, German Glioma Network.
    Int J Cancer; 2011 Aug 01; 129(3):659-70. PubMed ID: 21425258
    [Abstract] [Full Text] [Related]

  • 28. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M, Goeppert M, Felsberg J, Steiger HJ, Sabel M.
    Br J Neurosurg; 2013 Aug 01; 27(4):430-5. PubMed ID: 23418781
    [Abstract] [Full Text] [Related]

  • 29. Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
    Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall'Agata M, Eoli M, Della Puppa A, Pambuku A, D'Avella D, Berti F, Rudà R, Zagonel V.
    J Neurooncol; 2015 Nov 01; 125(2):359-67. PubMed ID: 26423801
    [Abstract] [Full Text] [Related]

  • 30. The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
    McDonald KL, Rapkins RW, Olivier J, Zhao L, Nozue K, Lu D, Tiwari S, Kuroiwa-Trzmielina J, Brewer J, Wheeler HR, Hitchins MP.
    Eur J Cancer; 2013 Jan 01; 49(2):360-8. PubMed ID: 22975219
    [Abstract] [Full Text] [Related]

  • 31. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
    SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z, LanXiao W, Fei Y.
    Cancer Sci; 2012 Feb 01; 103(2):269-73. PubMed ID: 22034964
    [Abstract] [Full Text] [Related]

  • 32. Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation.
    Lam N, Chambers CR.
    J Oncol Pharm Pract; 2012 Jun 01; 18(2):229-38. PubMed ID: 22065199
    [Abstract] [Full Text] [Related]

  • 33. O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.
    Spiegl-Kreinecker S, Pirker C, Filipits M, Lötsch D, Buchroithner J, Pichler J, Silye R, Weis S, Micksche M, Fischer J, Berger W.
    Neuro Oncol; 2010 Jan 01; 12(1):28-36. PubMed ID: 20150365
    [Abstract] [Full Text] [Related]

  • 34. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
    Pyko IV, Nakada M, Sabit H, Teng L, Furuyama N, Hayashi Y, Kawakami K, Minamoto T, Fedulau AS, Hamada J.
    Carcinogenesis; 2013 Oct 01; 34(10):2206-17. PubMed ID: 23715499
    [Abstract] [Full Text] [Related]

  • 35. Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.
    Park CK, Kim J, Yim SY, Lee AR, Han JH, Kim CY, Park SH, Kim TM, Lee SH, Choi SH, Kim SK, Kim DG, Jung HW.
    Neuro Oncol; 2011 Feb 01; 13(2):195-202. PubMed ID: 21075779
    [Abstract] [Full Text] [Related]

  • 36. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
    Adeberg S, Bernhardt D, Harrabi SB, Diehl C, Koelsche C, Rieken S, Unterberg A, von Deimling A, Debus J.
    J Neurooncol; 2016 Jun 01; 128(2):341-8. PubMed ID: 27025857
    [Abstract] [Full Text] [Related]

  • 37. Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
    Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, Nakasu Y, Abe T, Namba H, Wakai K, Wakabayashi T.
    Cancer; 2011 Apr 15; 117(8):1721-30. PubMed ID: 21472719
    [Abstract] [Full Text] [Related]

  • 38. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H, Li J, Cheng G, Zhang J, Li X.
    Clin Neurol Neurosurg; 2016 Dec 15; 151():31-36. PubMed ID: 27764705
    [Abstract] [Full Text] [Related]

  • 39. Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
    Bell EH, Pugh SL, McElroy JP, Gilbert MR, Mehta M, Klimowicz AC, Magliocco A, Bredel M, Robe P, Grosu AL, Stupp R, Curran W, Becker AP, Salavaggione AL, Barnholtz-Sloan JS, Aldape K, Blumenthal DT, Brown PD, Glass J, Souhami L, Lee RJ, Brachman D, Flickinger J, Won M, Chakravarti A.
    JAMA Oncol; 2017 Jun 01; 3(6):784-792. PubMed ID: 28097324
    [Abstract] [Full Text] [Related]

  • 40. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
    Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens EJ, Strauven T, D'Hondt LA, Sartenaer D, Califice SF, Bierau K, Svensson C, De Grève J, Neyns B.
    Eur J Cancer; 2009 Jan 01; 45(1):146-53. PubMed ID: 18945611
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.